SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novoste (novt)
NOVT 130.94+1.7%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Oak Tree who wrote (65)7/11/1999 6:01:00 PM
From: dr.john  Read Replies (1) of 100
 
Oak Tree,

have you any idea whether the IVBT-device being developed by Endosoncis' (ESON) recently acquired Navius-subsidiary could have any significant advantage over other devices, which are currently tested (and I think more advanced). ESONclaims that their "directional irradiation" (combined, of course with IVUS) might be superior to "general" intravascular irradiation; I doubt somewhat whether directional irradiation (focussing at the lumen-sites of most severe atheromatous disease) would be much superior to other techniques....

DrJohn
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News